On Apr. 14, 2021, Novavax announced its participation in an expanded investigator-initiated Phase 2 clinical trial called Comparing COVID-19 Vaccine Schedule Combinations ﾖ Stage 2 (Com-COV2), conducted by the University of Oxford and supported by the UK Vaccines Taskforce.

Novavax’ recombinant protein vaccine candidate, NVX-CoV2373, is one of four COVID-19 vaccines that studied to evaluate the potential for combined regimens that mix vaccines from different manufacturers to achieve immune protection against COVID-19.